Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial

Next Previous
X
Search
Trial Profile

Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tiratricol (Primary)
  • Indications Allan-Herndon-Dudley syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms Triac; Triac Trial I; TRIAC-1
  • Sponsors Rare Thyroid Therapeutics

    • Most Recent Events

    • 06 Sep 2024 According to an Egetis Therapeutics media release, data from this study have been published ahead of the 46th Annual Meeting of the European Thyroid Association.
    • 06 Sep 2024 Results published in an Egetis Therapeutics AB Media Release.
    • 27 Oct 2023 According to an Egetis Therapeutics media release, based on efficacy data from this trial, the Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Emcitate (tiratricol) for the treatment of MCT8 deficiency has been validated. The Emcitate MAA is under review by the Committee for Medicinal Products for Human Use (CHMP).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top